Infinity Pharmaceuticals PT Raised to $55.00 (INFI)
RBC Capital increased their price target on shares of Infinity Pharmaceuticals (NASDAQ: INFI) from $38.00 to $55.00 in a research note issued on Wednesday. The firm currently has an “outperform” rating on the stock.
A number of other analysts have also recently weighed in on INFI. Analysts at Stifel Nicolaus raised their price target on shares of Infinity Pharmaceuticals from $39.00 to $50.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of Infinity Pharmaceuticals in a research note to investors on Wednesday. They now have a $41.00 price target on the stock, up previously from $21.00. Finally, analysts at Piper Jaffray initiated coverage on shares of Infinity Pharmaceuticals in a research note to investors on Friday, March 1st. They set an “overweight” rating and a $53.00 price target on the stock.
Shares of Infinity Pharmaceuticals traded up 3.32% during mid-day trading on Wednesday, hitting $46.64. Infinity Pharmaceuticals has a one year low of $7.98 and a one year high of $46.81. The stock’s 50-day moving average is currently $37.10. The company’s market cap is $1.841 billion.
Infinity Pharmaceuticals, Inc. (IPI) is a drug discovery and development company. The Company’s lead product candidate, IPI-504 (retaspimycin hydrochloride), is an intravenously administered small molecule inhibitor of heat shock protein 90 (Hsp90).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.